PolyMedix Inc. Presents PMX-60056 Clinical Data at the American Heart Association Scientific Sessions Meeting

RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc (OTC BB: PMYX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).